Trial Profile
Correlative Analyses of Specimens From Eastern Cooperative Group Study E1608
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Sargramostim
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 16 May 2017 Status changed from not yet recruiting to completed.
- 17 Jun 2013 New trial record